Overall rank by patents
#2,030
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Nektar Therapeutics
USPTO PatentsView assignee record - 196 granted patents across 27 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).
196
Total patents granted
27
CPC technology areas
12.5
Avg claims per patent
-64%
5-year filing velocity
The verdict
Nektar holds 196 US patents across 27 technology areas, rank #2,030 of 50,000 tracked assignees.
- #2,030
- of 50,000 US assignees by volume
- Top 19%
- by Innovation Score (47.1/100)
- 12.5
- avg claims per patent
- -64%
- filing velocity, last 5 yrs
Portfolio overview
Nektar Therapeutics has been granted 196 US utility patents between 2015 and 2025, placing Nektar Therapeutics at rank #2,030 across all assignees tracked by PlainPatent. This portfolio spans 27 distinct Cooperative Patent Classification (CPC) subclasses, averaging 12.5 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a US Corporation, Nektar Therapeutics is one of the more focused assignees in the PatentsView dataset. By volume, Nektar sits between Sorin CRM SAS (197 patents, rank #2,026) and China Mobile Communications Group Co., Ltd. (195 patents, rank #2,034) - the closest US assignees by grant volume. The composite Innovation Score of 47.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 52 grants, compared with 144 in the 2015–2019 window, a -64% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Nektar Therapeutics's 12.5 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 27 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Nektar Therapeutics against peers pursuing similar technology classes.
Who files at Nektar's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Sorin CRM SAS
SORIN CRM SAS
197 patents
- Securus
Securus Technologies, LLC
197 patents
- Timotion Technolo…
TIMOTION TECHNOLOGY CO., LTD.
197 patents
- Biomet Sports Med…
Biomet Sports Medicine, LLC
196 patents
- Olympus Winter &…
OLYMPUS WINTER & IBE GMBH
196 patents
- Specialized Bicyc…
SPECIALIZED BICYCLE COMPONENTS, INC.
196 patents
- True Velocity IP…
True Velocity IP Holdings, Inc.
196 patents
- Nektar Therapeuti… ◀
Nektar Therapeutics
196 patents
- China Mobile Comm…
CHINA MOBILE COMMUNICATIONS GROUP CO., LTD.
195 patents
What this shows Nektar holds 196 patents at rank #2,030, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Nektar
By rank, the assignees closest to #2,030 in granted patent volume.
- Sorin CRM SAS #2,026 · 197 patents
- Securus Technologies, Llc #2,027 · 197 patents
- Timotion Technology Co., Ltd. #2,028 · 197 patents
- Biomet Sports Medicine, Llc #2,029 · 196 patents
- Olympus Winter & IBE Gmbh #2,031 · 196 patents
- Specialized Bicycle Components, Inc. #2,032 · 196 patents
- True Velocity IP Holdings, Inc. #2,033 · 196 patents
- China Mobile Communications Group Co., Ltd. #2,034 · 195 patents
Leaders in A61K (Preparations FOR Medical)
Other assignees with the most granted patents in Nektar's primary technology class.
- The Regents Of The University Of California 1,779 in class
- L'oreal 1,250 in class
- Novartis Ag 988 in class
- The Procter & Gamble Company 985 in class
- The Board Of Regents Of The University Of Texas System 950 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 813 in class
- The Trustees Of The University Of Pennsylvania 768 in class
- Merck Sharp & Dohme Llc 760 in class
Nektar's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
47 Top 19% higher than 81% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 41 | 20.9% |
| 2016 | 39 | 19.9% |
| 2017 | 27 | 13.8% |
| 2018 | 19 | 9.7% |
| 2019 | 18 | 9.2% |
| 2020 | 15 | 7.7% |
| 2021 | 12 | 6.1% |
| 2022 | 8 | 4.1% |
| 2023 | 7 | 3.6% |
| 2024 | 5 | 2.6% |
| 2025 | 5 | 2.6% |
Which technologies does Nektar Therapeutics patent most?
Top 15 of 27 technology areas
Patent Moat Analysis
Portfolio Volume Moderate
Tech Breadth Multi-domain
Claim Depth Standard
Velocity Declining
Frequently Asked Questions
How many patents does Nektar Therapeutics hold?
Nektar Therapeutics holds 196 US granted patents filed between 2015 and 2025, spanning 27 technology areas.
What is Nektar Therapeutics's Innovation Score?
Nektar Therapeutics has an Innovation Score of 47.1 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Nektar Therapeutics focus on?
Nektar Therapeutics's top technology area is A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES) with 175 patents. The company has filed patents in 27 CPC subclasses total.
Is Nektar Therapeutics's patent filing rate increasing or decreasing?
Nektar Therapeutics's recent filing velocity is -64% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Nektar Therapeutics's patents?
Nektar Therapeutics's patents average 12.5 claims each. This falls within the standard range, providing solid legal coverage.
How is the Nektar Therapeutics patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Nektar's 196 grants land it in the top 19% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Nektar ranks #2,030 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61K - see who else leads that technology area. A61K leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.